share_log

Vivos Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Vivos Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Vivos Therapeutics | S-1/A：證券上市註冊聲明(修正)
美股sec公告 ·  04/22 12:58
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a medical technology company, has filed an Amendment No. 1 to Form S-1 with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024, under Registration No. 333-278564. This amendment updates the Incorporation of Certain Information by Reference section of the original Registration Statement on Form S-1 filed on April 9, 2024. The amendment does not reflect any other changes or events post the original filing date. The prospectus relates to the offer for sale of up to 1,737,259 shares of common stock by a selling stockholder, which includes shares underlying common stock purchase warrants issued in private placements on January 9, 2023, and February 20, 2024. Vivos Therapeutics will not receive proceeds from the resale of shares but may receive proceeds upon exercise of the warrants. The company has received regulatory approvals for Medicare reimbursement for its oral medical devices in April 2024. The common stock is listed on Nasdaq under the symbol 'VVOS'.
Vivos Therapeutics, Inc., a medical technology company, has filed an Amendment No. 1 to Form S-1 with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024, under Registration No. 333-278564. This amendment updates the Incorporation of Certain Information by Reference section of the original Registration Statement on Form S-1 filed on April 9, 2024. The amendment does not reflect any other changes or events post the original filing date. The prospectus relates to the offer for sale of up to 1,737,259 shares of common stock by a selling stockholder, which includes shares underlying common stock purchase warrants issued in private placements on January 9, 2023, and February 20, 2024. Vivos Therapeutics will not receive proceeds from the resale of shares but may receive proceeds upon exercise of the warrants. The company has received regulatory approvals for Medicare reimbursement for its oral medical devices in April 2024. The common stock is listed on Nasdaq under the symbol 'VVOS'.
醫療技術公司Vivos Therapeutics, Inc. 已於2024年4月19日向美國證券交易委員會（SEC）提交了S-1表格的第1號修正案，註冊號爲333-278564。該修正案更新了2024年4月9日提交的S-1表格原始註冊聲明中的 “以引用方式納入某些信息” 部分。該修正案未反映原始申請日期之後的任何其他變更或事件。招股說明書涉及賣出股東出售最多1,737,259股普通股的要約，其中包括2023年1月9日和2024年2月20日以私募方式發行的標的普通股購買權證。Vivos Therapeutics不會從股票轉售中獲得收益，但可能會在行使認股權證時獲得收益。該公司已於2024年4月獲得監管部門批准其口腔醫療器械的醫療保險報銷。普通股在納斯達克上市，股票代碼爲 “VVOS”。
醫療技術公司Vivos Therapeutics, Inc. 已於2024年4月19日向美國證券交易委員會（SEC）提交了S-1表格的第1號修正案，註冊號爲333-278564。該修正案更新了2024年4月9日提交的S-1表格原始註冊聲明中的 “以引用方式納入某些信息” 部分。該修正案未反映原始申請日期之後的任何其他變更或事件。招股說明書涉及賣出股東出售最多1,737,259股普通股的要約，其中包括2023年1月9日和2024年2月20日以私募方式發行的標的普通股購買權證。Vivos Therapeutics不會從股票轉售中獲得收益，但可能會在行使認股權證時獲得收益。該公司已於2024年4月獲得監管部門批准其口腔醫療器械的醫療保險報銷。普通股在納斯達克上市，股票代碼爲 “VVOS”。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息